
21 settembre 2023
Hereditary tumors
From research to clinical practice
Responsabili scientifici
President
Fabio Landoni
Directors
Robert Fruscio, Domenica Lorusso
Razionale
Oncologic prevention based on genetic risk assessment is a relatively recent field in medicine. From the early 90s, when BRCA1 and BRCA2 have been identified, sequencing technologies have greatly improved, and the role of pathogenic mutations in increasing the risk of developing cancer has been unraveled. Moreover, among women with epithelial ovarian cancer, the discovery of mutations in genes involved in the homologous recombination pathway has led to the introduction in the clinical practice od a new class of anticacner drugs, the PARP inhibitors, that significantly changed the prognosis of these women. However, the most effective preventive strategy of women with pathogenic genetic mutations is not completely estabilished, and there are many questions about the optimal management of healthy women that remain unanswered. This event will be an opportunity to discuss the state of the art and the most controversial issues with Professor Steven Narod, Professor Joanne Kotsopoulos and Professor Kelly Metcalfe from Toronto, who are among the world opinion leaders on this topic, and with other national renowned experts.
Risorse
